Allergy & Clinical Immunology Perspective and Journal Articles

 
 

  • After Hundreds of Interviews, Here's John Whyte's View of COVID   Our problem with vaccines is that we talk about people instead of talking with people and listening to their perspectives.
  • First Month of COVID-19 Vaccine Safety Monitoring Reassuringly, in the initial month of administering 13.8 million doses of Pfizer-BioNTech and Moderna COVID-19 vaccines to the U.S. population, no serious safety issues were found.
  • Radiological and Functional Lung Sequelae of COVID-19 A follow-up of COVID-19 patients provides insight into the radiological findings and lung function after recovery.
  • How HIPAA Can Harm Patients As Dr Andrew Wilner has experienced first-hand, HIPAA may not always be in the patient's best interest.
  • ISAD 2021 Read clinically focused news coverage of key developments from ISAD 2021.
  • Efficacy and Safety of Covid-19 Vaccines in Older People This article summarizes the main COVID-19 vaccines, both approved and currently in trial, with a focus on the evidence of their safety and efficacy in the older population and those with frailty.
  • Medscape Physician Compensation Report 2021: The Recovery Begins Physician compensation was atypical in 2020 due to the COVID pandemic. Almost 18,000 physicians told us about their income, bonus, hours worked, and greatest work challenges.
  • Has the U.S. Entered a Fourth Wave?   WebMD's Chief Medical Officer, John Whyte, MD, speaks with Eric Topol, MD, Executive VP, Scripps Research, Editor-in-Chief, Medscape, about the fourth wave of the pandemic that the United States may be facing.
  • When Does a Person Become Your Patient? You get a phone call from a 'friend of a friend' asking for advice. Or you find a new problem (in a current patient) that's outside your expertise. What's your duty of care in each case?
  • Tralokinumab for Atopic Dermatitis: A Promising New Therapy Multiple trials of tralokinumab, an interleukin-13 inhibitor, indicate that it is a promising treatment option for patients with moderate-to-severe atopic dermatitis.
  • Improve Doctor-Patient Relationships With This One Question After personal tragedy struck, Dr Doug Lake found himself more closely considering his patients' experiences, completely changing how he interacted with them.
  • Roberto Burioni on Conquering COVID and Charming the Skeptics   Virologist-author Roberto Burioni talks about the relevance of variants, why vaccines are our ticket out of this nightmare, and how best to deal with science and vaccine skeptics.
  • Why Obesity May Worsen COVID-19 Outcomes   WebMD's Chief Medical Officer, John Whyte, MD, speaks with Fatima Cody Stanford, MD, obesity medicine physician, Massachusetts General Hospital & Harvard Medical School, about the disease of obesity as a comorbidity risk factor for COVID-19.
  • Defending My Right to Mask In looking at common masking practices in Asia, Dr George Lundberg found a model for how to care for our fellow citizens here in the United States.
  • Allergic Reactions, Anaphylaxis After Moderna COVID-19 Vaccine This report summarizes the clinical and epidemiologic characteristics of allergic reactions, including anaphylaxis and nonanaphylaxis reactions, after receipt of the Moderna COVID-19 vaccine.
  • Vancomycin Induced Cardiac Arrest: A Case Report This case underscores the need to be familiar with Red Man Syndrome, a rare but potentially life threatening adverse effect of vancomycin.
  • The Revenge of the 'Late COVID Adopters' The urgency of COVID complications has led to a rush to find treatment strategies as quickly as possible. But, as your grandmother said, sometimes haste makes waste.
  • Clinical Advances in Rhinosinusitis From AAAAI 2021   Dr Anju Peters talks through the latest data from AAAAI 2021 on the impact of the biologics dupilumab and mepolizumab on patient outcomes and health-related quality of life in rhinosinusitis.
  • Key Presentations on Hereditary Angioedema From AAAAI 2021   Highlights from AAAAI 2021 on hereditary angioedema include results from the APeX-2 trial, which led to the approval of berotralstat, and the HELP study, which assessed the efficacy of lanadelumab.
  • COVID-19: When Will Our Lives Be 'Normal' Again?   Dr Art Caplan describes what daily life may become as more people get COVID vaccines.